Unsere Publikationen

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Link
https://doi.org/10.1177/20552173221142741
Tags
Multiple SkleroseMS Behandlung
Jahr
2023
Autoren
Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, Hartung HP, Havrdova EK, LaGanke CC, Ziemssen T, Van Wijmeersch B, Meuth SG, Margolin DH, Poole EM, Baker DP, Senior PA.
Verlag
Mult Scler J Exp Transl Clin. 2023 Jan 3;9(1):20552173221142741.
Zum Eintrag

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Link
https://doi.org/10.1177/17562864221150040
Tags
Multiple SkleroseMS Behandlung
Jahr
2023
Autoren
Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T.
Verlag
Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040.
Zum Eintrag

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

Link
https://doi.org/10.1073/pnas.2207291120
Tags
Multiple SkleroseMS BehandlungNeuroimmunologie
Jahr
2023
Autoren
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von Büdingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, Bar-Or A.
Verlag
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2207291120.
Zum Eintrag

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

Link
https://doi.org/10.3390/vaccines10122167
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Ziemssen T, Groth M, Ettle B, Bopp T.
Verlag
Vaccines (Basel). 2022 Dec 16;10(12):2167.
Zum Eintrag

The need for a strategic therapeutic approach: multiple sclerosis in check

Link
https://doi.org/10.1177/20406223211063032
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Inojosa H, Proschmann U, Akgün K, Ziemssen T.
Verlag
Ther Adv Chronic Dis 2022;13.
Zum Eintrag

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Link
https://doi.org/10.1177/20552173221085741
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Koeditz D, Frensch J, Bierbaum M, Ness NH, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T.
Verlag
Mult Scler J Exp Transl Clin. 2022 Mar 29;8(1):20552173221085741.
Zum Eintrag

Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE

Link
https://doi.org/10.1177/17562864221090398
Tags
Multiple SkleroseMS BehandlungMobilität
Jahr
2022
Autoren
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T, Hobart J.
Verlag
Ther Adv Neurol Disord. 2022 May 18;15:17562864221090398.
Zum Eintrag

Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more

Link
https://doi.org/10.1080/17425255.2022.2138330
Tags
Multiple SkleroseMS Behandlung
Jahr
2022
Autoren
Constantinescu V, Akgün K, Ziemssen T.
Verlag
Expert Opin Drug Metab Toxicol 2022;18(10):675-693.
Zum Eintrag
3 4 5 6 7

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-